Annovis Bio to Host Investor Webcast on Lead Drug Candidate Buntanetap

Annovis Bio

MALVERN, PAAnnovis Bio Inc. (NYSE: ANVS) announced it will host an investor webcast on June 11, 2024, at 4:30 p.m. ET to discuss recent developments and future plans for its lead drug candidate, Buntanetap.

The webcast will cover advancements in the development of Buntanetap, strategic plans for upcoming clinical trials, and an overview of the company’s progress and future direction.

Annovis Bio encourages investors and interested parties to register in advance. This webcast offers a chance for stakeholders to gain insights into the company’s efforts to bring innovative treatments to market.

Buntanetap is being developed to address neurodegenerative diseases, a field with significant unmet medical needs. The investor call aims to provide clarity on its potential impact and Annovis Bio’s growth strategy.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.

READ:  Annovis Bio's Alzheimer's Drug Shows Promise in Phase II/III Trial